In conclusion, this report underscores the efficacy of selpercatinib for RET fusion-positive tumors beyond lung and thyroid cancers, supporting its integration into the treatment paradigm for diverse RET-altered malignancies. The gene discussed is RET; the disease is thyroid gland carcinoma.